Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
about
Statins for the primary prevention of cardiovascular diseaseStatins for the primary prevention of cardiovascular diseaseEffects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefitRegulatory challenges for new drugs to treat obesity and comorbid metabolic disordersThe Effects of Chunghyul-Dan (A Korean Medicine Herbal Complex) on Cardiovascular and Cerebrovascular Diseases: A Narrative ReviewATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatinHMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statinsAssociation between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings.Do HMG-CoA reductase inhibitors affect fibrinogen?Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.Elderly patients at risk for coronary heart disease or stroke: selecting an ideal product for lipid lowering.Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDLLiver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature.3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase.Model-based development of gemcabene, a new lipid-altering agent.Statin wars following coronary revascularization--evidence-based clinical practice?Statins as first-line therapy for acute coronary syndrome?Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.Plasma Coenzyme Q10 Predicts Lipid-lowering Response to High-Dose AtorvastatinStatins in the first-line therapy of acute coronary syndrome - similar to aspirin?Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study.A systematic review and meta-analysis on the therapeutic equivalence of statins.Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians.On the origin of 3-methylglutaconic acid in disorders of mitochondrial energy metabolismCoenzyme Q(10) and statin myalgia: what is the evidence?Statins and modulation of oxidative stress.Plasma fibrinogen level and long-term prognosis in Norwegian middle-aged patients with previous myocardial infarction. A 10 year follow-up study.Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins.Efficacy of alternate-day dosing versus daily dosing of atorvastatin.Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.Simulating titration to goal clinical trials with statins.Statin drugs do not affect serum complement activation in vitro.Acute administration of red yeast rice (Monascus purpureus) depletes tissue coenzyme Q(10) levels in ICR mice.Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
P2860
Q24201513-07D3E05A-32DE-47AE-8D80-F0FEFF02253CQ24234813-0D69ACC0-13B8-4623-B44B-5EE26777AEB0Q24650533-74DAA157-6647-41C0-B11E-47CE35D7F58FQ24658031-3B6CE37A-A04E-4FC0-9DBD-97301D90428AQ26747311-E09169B6-AC43-4CAB-A4C2-12F481910BE0Q28236930-8C677EAC-7755-4D4A-8236-E9D2E2552B01Q28344912-C7E85221-118D-46AF-AE83-4DEEA4ED47AEQ30654115-290289BC-15A8-4975-B967-C9AAD0C273F4Q32052986-B63B9CD8-2F84-473C-ADB3-6EEB4B127AD7Q33935872-0F325A62-DF21-4028-817E-EE0AE28896FEQ34122524-C4FF774A-A257-4501-AD17-30D71C01B342Q34186428-67D0B583-0C24-4499-A8F4-F361CAD707ADQ34559971-ED5EB753-6FE0-4A0B-A0BE-55F04D707AE1Q35009456-E14A1AEB-9A5F-43F9-A356-9061693E15A1Q35564280-07621724-453D-4887-8F15-0A58A158960FQ35637087-52E332A9-B09B-4726-838E-A6DC0EA265E2Q35654989-86680EEA-18E8-4109-B493-56BDB9BD8688Q36341650-1E10E987-6AA2-49E8-9A84-A591EE595FA9Q36383378-9E70ECC3-027D-46F5-86E6-6123E6C91DC0Q36768488-AEC72C31-4C6A-4783-8746-15BEB658880AQ36894180-69586997-4067-4AB7-A60A-D147F4BD33B3Q37005510-8CFDDE38-4402-470C-BEDC-BE6C18C89C88Q37276466-08C06850-8360-43D5-A959-14E9FDA91510Q37644907-1D8626A2-0917-4D22-A095-E330EAD9A59BQ37747986-B0094C64-045A-424A-B96C-9A6BAAC2DC3DQ38549355-4980017F-BF68-479B-A95E-2E72DB29221BQ38817615-2D06A20B-8E85-457C-977F-98D2E6984CB1Q41391827-A9F78D15-353E-46D7-A7CA-31F1BA138014Q41700092-5EABFA02-15E8-4171-A5E3-CDD9916BA708Q42931503-8C5011AE-942A-4FCD-9C84-E5C652952DDEQ43215640-110C4BB1-226C-4144-9727-95FE69297F40Q43651150-0092ACEA-382A-4877-8AF5-92532826BF7CQ43673213-076E46EC-88E0-4B04-AB5D-C443F835C73CQ44479265-36A612DC-1803-478C-A403-39BCBAABFCB0Q44874910-589038D1-217A-4E06-BE8D-43F2A269DB38Q44877647-258422C7-E750-4900-AF43-7B22EF117D7FQ44943594-CED96CED-A147-463D-93CA-7E0CBC997E92Q44967045-5E993AFD-E83C-4809-B8F6-5ABC274E1340Q45260738-EA89D84A-5BB6-4801-BC79-910B61EF7C71Q46816646-CC5D0E13-76D7-4A0A-8FC5-A59679E90573
P2860
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@ast
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@en
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@nl
type
label
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@ast
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@en
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@nl
prefLabel
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@ast
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@en
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@nl
P2093
P1476
Comparison of one-year efficac ...... a. Atorvastatin Study Group I.
@en
P2093
Bakker-Arkema R
Davidson M
McKenney J
P304
P356
10.1016/S0002-9149(97)00174-4
P407
P577
1997-06-01T00:00:00Z